Skip to Content

Timber Pharmaceuticals Inc Ordinary Shares TMBR Stock Quote

| Rating as of

Morningstar‘s Stock Analysis TMBR

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics TMBR

Company Profile TMBR

Business Description

Timber Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. It is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and scleroderma. The company's development pipeline includes TMB-001 (Topical Isotretinoin), TMB-002 (Topical Rapamycin), and TMB-003 (Topical / Subcutaneous ET-A Receptor Antagonist).

Contact
110 Allen Road, Suite 401
Basking Ridge, NJ, 07920
T +1 973 314-9577
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type
Employees 5